When did obesity become a drug deficiency?

This is especially important in older patients, in whom sarcopenia, frailty, falls, osteoporosis, and loss of functional independence already represent major clinical concerns. Skeletal muscle is not decorative tissue. It is central to glucose disposal, mobility, balance, strength, metabolic reserve, and resilience during acute illness.

A 35-year-old with severe obesity losing some lean mass during substantial fat reduction is not clinically equivalent to a frail 78-year-old doing the same. Responsible obesity medicine therefore cannot consist simply of prescribing an injection and celebrating weight loss. Nutrition, adequate protein intake, resistance exercise, physical function, and muscle preservation should become integral parts of treatment. The goal is not to make patients lighter. The goal is to make them healthier.

The economics of treating the consequence

This discussion has an uncomfortable economic dimension that does not require conspiracy theories or accusations of bad faith. Modern health care is exceptionally effective at creating financial structures around treatment. A pharmaceutical product can be researched, patented, manufactured, marketed, prescribed, reimbursed, monitored, and administered repeatedly. Hospitals can build programs around it. Insurers can establish coverage criteria for it. Physicians can prescribe it. Investors can calculate its market. Patients can measure its effects. The entire structure of modern medicine understands how to assign economic value to an intervention.

Prevention is different. No comparable recurring revenue stream is generated when a child grows up eating mostly minimally processed food, sleeping adequately, walking and exercising regularly, maintaining muscle, and never developing metabolic disease. No blockbuster pharmaceutical product is called adequate sleep, no patent exists on resistance exercise, and no quarterly earnings call celebrates the number of patients who never became sick. That does not mean pharmaceutical companies created the obesity epidemic. It means that our economic system has far more powerful mechanisms for rewarding treatment than for rewarding the absence of disease.

The result can emerge without anyone designing it. Industry develops products that generate returns. Physicians work within reimbursement systems built around identifiable diagnoses and interventions. Insurers reimburse treatments meeting defined criteria. Hospitals organize programs around services they can deliver and bill. Patients understandably prefer interventions that produce meaningful results, particularly after years of unsuccessful attempts at weight loss.

Each participant can behave rationally, yet the system can drift toward a remarkable destination: we construct an environment that promotes metabolic dysfunction and then build an increasingly sophisticated medical economy around helping people survive it.

Now the government is buying in

This discussion became even more consequential in 2026. Beginning July 1, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge, a demonstration program providing eligible Medicare Part D beneficiaries access to certain GLP-1 drugs with a $50 copayment. The program is scheduled to continue through December 31, 2027.[19] Whatever one thinks about the policy, it represents an important transition. GLP-1 therapy for obesity is no longer simply a matter between an individual patient, physician, insurer, and manufacturer. The federal government is now directly participating in expanded access.

For many patients, this may be excellent news. Obesity disproportionately affects populations that often have the least access to effective treatment, and cost has been a substantial barrier to modern obesity pharmacotherapy. If these medications reduce cardiovascular events, diabetes, kidney disease, sleep apnea, disability, and other obesity-related complications, expanding access may ultimately prove both humane and economically rational. Those outcomes should be studied carefully, not presumed.

But public financing also creates a public obligation to ask what we are buying. Are we purchasing durable reductions in cardiovascular disease, diabetes, disability, and mortality? Are we reducing total health-care expenditure over time? Are patients becoming stronger and metabolically healthier, or simply lighter? What happens after five, ten, or twenty years of treatment? What proportion of patients remain on therapy? What happens to those who discontinue it? What are the nutritional and functional consequences in older adults? And perhaps most importantly, how much are we simultaneously investing in understanding and modifying the conditions that made treatment necessary?

Those questions are not arguments against coverage. They are precisely the questions that should accompany responsible coverage.

Medicine must be able to hold two ideas at once

Public debates increasingly demand that we choose teams. Either GLP-1 drugs are miracle therapies that should be celebrated without reservation, or they are dangerous pharmaceutical shortcuts that should be rejected in favor of diet and exercise. Both positions are intellectually unsatisfying. Medicine should be able to hold two ideas simultaneously, particularly when both are supported by evidence.

The first is that GLP-1-based therapies represent a major medical advance. They produce substantial weight loss, improve important metabolic parameters, and have demonstrated benefits extending to cardiovascular outcomes, kidney outcomes, and obstructive sleep apnea in appropriately selected populations. [5,6,13] For many patients, they may prevent disease, restore mobility, improve quality of life, and possibly extend survival. Patients who benefit from them should not be ashamed for using them any more than a patient with hypertension should be shamed for taking an antihypertensive medication.